mims-harvard/tooluniverse-rare-disease-diagnosis
skills/tooluniverse-rare-disease-diagnosis/SKILL.md
Rare disease differential diagnosis from patient phenotype — HPO term matching to candidate diseases (Orphanet, OMIM), gene panel prioritization, ACMG variant interpretation, and structure-based variant analysis. Use for diagnostic odyssey assistance, phenotype-to-disease ranking, and genetic-counseling differential generation.
$ install --global
skillsauthnpx skillsauth add mims-harvard/tooluniverse tooluniverse-rare-disease-diagnosisInstall this skill globally with one command. Works with Claude Code, Cursor, and Windsurf.
Security Scan Results
3 of 9 scanners reported clean
Some scanners were skipped, did not run, or reported a non-clean status. Review each row below.
3
Scanners Passed
9
Scanners in report
Clean
TrivyContainer and dependency vulnerability scanner
95%
Clean
SemgrepStatic code analysis for vulnerabilities
95%
Clean
mcp-scan (Snyk)Model Context Protocol security validation
95%
Skipped
Snyk (dep)Open source security scanning
50%
Skipped
Socket.devSupply chain security analysis
50%
Skipped
VirusTotalMulti-engine malware detection
50%
Skipped
CrowdStrikeAdvanced threat intelligence
50%
Skipped
OSV-ScannerOpen Source Vulnerability database check
50%
Skipped
OWASP Dep-Check
50%
Last scanned: May 26, 2026, 7:15 AM30.8s7 files scanned
SKILL.md
- name:
- tooluniverse-rare-disease-diagnosis
- description:
- Rare disease differential diagnosis from patient phenotype — HPO term matching to candidate diseases (Orphanet, OMIM), gene panel prioritization, ACMG variant interpretation, and structure-based variant analysis. Use for diagnostic odyssey assistance, phenotype-to-disease ranking, and genetic-counseling differential generation.
- disable-model-invocation:
- true
Rare Disease Diagnosis Advisor
Systematic diagnosis support for rare diseases using phenotype matching, gene panel prioritization, and variant interpretation across Orphanet, OMIM, HPO, ClinVar, and structure-based analysis.
KEY PRINCIPLES:
- Report-first - Create report file FIRST, update progressively
- Phenotype-driven - Convert symptoms to HPO terms before searching
- Multi-database triangulation - Cross-reference Orphanet, OMIM, OpenTargets
- Evidence grading - Grade diagnoses by supporting evidence strength
- English-first queries - Always use English terms in tool calls
LOOK UP, DON'T GUESS
When uncertain about any scientific fact, SEARCH databases first rather than reasoning from memory.
COMPUTE, DON'T DESCRIBE
When analysis requires computation (statistics, data processing, scoring, enrichment), write and run Python code via Bash. Don't describe what you would do — execute it and report actual results. Use ToolUniverse tools to retrieve data, then Python (pandas, scipy, statsmodels, matplotlib) to analyze it.
Clinical Reasoning Framework (BEFORE Tools)
Apply these strategies to form a 3-5 candidate differential, then use tools to confirm/refute:
- Multi-system involvement - Symptoms spanning 2+ organ systems = strongest rare disease signal. Ask: what single pathway explains ALL features?
- Regression question - Losing abilities vs never acquired? Regression = neurodegenerative/metabolic storage. Stable = developmental/structural.
- Trigger question - Episodic/triggered (fasting, illness, exercise) = metabolic disorder (often treatable). Constitutive = structural/degenerative.
- Rarest feature first - Build differential from most specific finding, not most prominent. Check remaining features for consistency.
- Treatable-first - Move treatable conditions to top for urgent workup (enzyme replacement, dietary, chelation, vitamin-responsive).
- Occupational/environmental exposure - Latency up to 50 years. Asbestos/silica/heavy metals/solvents/farming. Always ask about PAST jobs.
- Autoimmune differential - Which joints? Symmetric? Extra-articular? Serologic pattern? Organ under attack?
- Rare syndrome signals - Named triads, common diagnoses failing to explain ALL findings, failed standard treatment, unusual lab findings.
- Tools verify, not generate - Form hypothesis first, then use databases to confirm.
Common pitfalls: Felty's (RA+splenomegaly+neutropenia) mimics infection; SLE nephritis mimics PSGN (check ASO); occupational exposures trigger autoimmunity (silica→scleroderma/RA/SLE).
Tool Parameter Corrections
| Tool | WRONG | CORRECT |
|------|-------|---------|
| OpenTargets_get_associated_drugs_by_target_ensemblID | ensemblID | ensemblId |
| ClinVar_get_variant_details | variant_id | id |
| MyGene_query_genes | gene | q |
| gnomad_get_variant | variant | variant_id |
Workflow
Phase 0: Clinical Reasoning → 3-5 candidate differential
Phase 1: Phenotype → HPO terms (HPO_search_terms), core vs variable, onset, family history
Phase 2: Disease Matching → Orphanet_search_diseases, OMIM_search, DisGeNET_search_gene
Phase 3: Gene Panel → ClinGen validation, GTEx expression, prioritization scoring
Phase 3.5: Expression Context → CELLxGENE, ChIPAtlas for tissue/cell-type confirmation
Phase 3.6: Pathway Analysis → KEGG, IntAct for convergent pathways
Phase 4: Variant Interpretation → ClinVar, gnomAD frequency, CADD/AlphaMissense/EVE/SpliceAI, ACMG criteria
Phase 5: Structure Analysis → AlphaFold2, InterPro domains (for VUS)
Phase 6: Literature → PubMed, BioRxiv/MedRxiv, OpenAlex
Phase 7: Report Synthesis → Prioritized differential with next steps
Key Phase Details
Phase 2 - Disease Matching: Orphanet_search_diseases(operation="search_diseases", query=keyword) then Orphanet_get_genes(operation="get_genes", orpha_code=code). Score overlap: Excellent >80%, Good 60-80%, Possible 40-60%.
Phase 3 - Gene Panel: ClinGen classification drives inclusion (Definitive/Strong/Moderate = include; Limited = flag; Disputed/Refuted = exclude). Scoring: Tier 1 (top disease gene +5), Tier 2 (multi-disease +3), Tier 3 (ClinGen Definitive +3), Tier 4 (tissue expression +2), Tier 5 (pLI >0.9 +1).
Phase 4 - Variants: gnomAD frequency classes: ultra-rare <0.00001, rare <0.0001, low-freq <0.01. ACMG: PVS1 (null), PS1 (same AA), PM2 (absent pop), PP3 (computational), BA1 (>5% AF). 2+ concordant predictors strengthen PP3.
Evidence Grading
| Tier | Criteria | |------|----------| | T1 (High) | Phenotype match >80% + gene match | | T2 (Medium-High) | Phenotype match 60-80% OR likely pathogenic variant | | T3 (Medium) | Phenotype match 40-60% OR VUS in candidate gene | | T4 (Low) | Phenotype <40% OR uncertain gene |
Fallback Chains
| Primary | Fallback 1 | Fallback 2 |
|---------|------------|------------|
| get_joint_associated_diseases_by_HPO_ID_list | Orphanet_search_diseases | PubMed phenotype search |
| ClinVar_get_variant_details | gnomad_get_variant | VEP annotation |
| GTEx_get_expression_summary | HPA_search_genes_by_query | Tissue-specific literature |
Reference Files
- DIAGNOSTIC_WORKFLOW.md - Code examples and algorithms per phase
- REPORT_TEMPLATE.md - Report template and examples
- CHECKLIST.md - Interactive completeness checklist
scripts/clinical_patterns.py- Clinical pattern lookup (syndromes, differentials, red flags, occupational exposures)
Related Skills
mims-harvard/tooluniverse-primer-design
tools
VerifiedTrustedCommunity
PCR / qPCR primer and oligo design — design forward/reverse primers for a target region (SantaLucia nearest-neighbor thermodynamics), compute melting temperature (Tm) and annealing temperature (Ta), check GC content, and screen an oligo for hairpins and primer-dimers. Use when you need primers for a sequence, want to QC an existing primer pair, or need the Tm of an oligo. Covers the primer-design rules (Tm matching, GC clamp, 3'-end, length) and the tools' constraint quirks.
1,414SKILL.mdUpdated Jun 4, 2026
mims-harvard/tooluniverse-pharmacokinetics
tools
VerifiedTrustedCommunity
Pharmacokinetic (PK) analysis of concentration-time data — non-compartmental analysis (NCA) for Cmax, Tmax, AUC (0-t and 0-∞), terminal half-life, clearance (CL), volume of distribution (Vd), MRT, and absolute bioavailability (F). Also one-compartment fitting. Use when you have plasma/serum drug concentrations over time after a dose and need PK parameters, or to compute bioavailability from IV + oral AUCs. NOT for ADMET property prediction from structure (use tooluniverse-admet-prediction).
1,414SKILL.mdUpdated Jun 4, 2026
mims-harvard/tooluniverse-molecular-cloning
tools
VerifiedTrustedCommunity
Molecular cloning assembly design — Gibson Assembly (overlap design for seamless multi-fragment joining) and Golden Gate Assembly (Type IIS / BsaI / BbsI design with unique 4-bp fusion overhangs). Use when you need to plan how to join DNA fragments into a construct, design assembly overlaps/overhangs, or decide between cloning methods. Covers the domestication (internal-site removal), overhang-uniqueness, and overlap-Tm rules. For PCR primers to generate the fragments, see tooluniverse-primer-design.
1,414SKILL.mdUpdated Jun 4, 2026
mims-harvard/tooluniverse-meta-analysis
tools
VerifiedTrustedCommunity
Meta-analysis / evidence synthesis — pool effect sizes across studies (odds ratios, risk ratios, hazard ratios, mean differences, correlations, GWAS betas) with fixed- or random-effects models, quantify heterogeneity (Q, I², τ²), and build a forest plot. Use when you have results from MULTIPLE studies and need a single pooled estimate, or to synthesize evidence from a systematic review / multiple GWAS / replicated experiments. Handles the error-prone effect-size + standard-error preparation (converting OR/HR/CI, two-group means±SD, proportions, and correlations into the (effect, SE) the pooling step needs).
1,414SKILL.mdUpdated Jun 4, 2026